Why Are People Talking About Investing in LNTH?

With gains of 2.2%, Lantheus was one of the winners on Wall Street today. Its shares are now trading at $84.89 and have logged a -1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

  • Lantheus has moved 41.5% over the last year, and the S&P 500 logged a change of -7.0%

  • LNTH has an average analyst rating of buy and is -21.67% away from its mean target price of $108.38 per share

  • Its trailing earnings per share (EPS) is $0.41

  • Lantheus has a trailing 12 month Price to Earnings (P/E) ratio of 207.1 while the S&P 500 average is 15.97

  • Its forward earnings per share (EPS) is $5.55 and its forward P/E ratio is 15.3

  • The company has a Price to Book (P/B) ratio of 12.8 in contrast to the S&P 500's average ratio of 2.95

  • Lantheus is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16

  • The company has a free cash flow of $-138,542,752.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter

  • Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS